KEY DETAILS
Massachusetts General Hospital has registered a Phase 2 pilot trial testing semaglutide for cannabis use disorder, not yet recruiting, with a listed start in January 2027.
Eli Lilly's Phase 3 trial will test its EloraTZP combination against tirzepatide, eloralintide, and placebo in adults with obesity, with a listed completion date of November 2029.
A second Lilly Phase 3 trial compares EloraTZP against tirzepatide alone in people with obesity or overweight and type 2 diabetes, also not yet recruiting.
A meta-analysis in Diabetes, Obesity and Metabolism found the available evidence insufficient to determine whether semaglutide is associated with changes in handgrip strength.
Three of these four items are trials that have not yet started recruiting, so they say less about quick answers than about how much is still ahead. Two trials from Eli Lilly and one from Massachusetts General Hospital are registered, with completion dates years away. A separate meta-analysis of existing semaglutide data shows how much uncertainty remains even for questions researchers have already studied. Most of what is new here is a plan, not a result.
Massachusetts General Hospital has registered a Phase 2 pilot trial testing semaglutide for cannabis use disorder. The study is not yet recruiting, and its listed start date is January 2027, with completion planned for March 2029. Researchers want to learn whether semaglutide affects brain reactivity to cannabis-related cues and whether it can safely reduce how often participants use cannabis. Participants in the study would receive weekly injections of semaglutide, at doses between 0.25 and 0.5 mg, across eight weeks. The listed enrollment is 40 adults. This is an early-stage plan, so there is nothing to report beyond the registration itself.
Eli Lilly has registered a Phase 3 trial comparing its EloraTZP combination, which pairs eloralintide and tirzepatide, against tirzepatide alone, eloralintide alone, and placebo in adults with obesity. The trial is not yet recruiting, with planned enrollment of 2,115 participants. Its listed start date is December 2026, and its completion date is set for November 2029, so any results are still years out. Participation in the study would last about two years.
A second Lilly Phase 3 trial also tests EloraTZP, this time against tirzepatide alone, in adults with obesity or overweight who also have type 2 diabetes. This trial is not yet recruiting either, with planned enrollment of 1,000 participants. Its listed start date is November 2026, and its completion date is also set for November 2029. As with the first trial, participation would last about two years.
A meta-analysis in Diabetes, Obesity and Metabolism looked at whether semaglutide is associated with changes in muscle strength, measured by handgrip strength. The analysis found the available evidence insufficient to determine this, because the main synthesis relied on uncontrolled within-group changes, with very low certainty and significant heterogeneity. The authors say these findings do not establish strength preservation or a causal treatment effect.
The trial registrations are listed on ClinicalTrials.gov under NCT07879612, NCT07881432 and NCT07881458, and the meta-analysis is published in Diabetes, Obesity and Metabolism (DOI 10.1111/dom.71432).
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.